• Home
    • Leucémie myéloïde chronique
    • Leucemia Mieloide Crónica
  • CML Experts
    • How to get the CMLer's password?
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • CML experts in America >
      • CML experts in Canada >
        • How to get the CMLer's password?
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connie Eaves
        • Dr. Josée Hébert
        • Dr. Vincent Éthier
        • Dr. Marc Lalancette
        • Dr. Luigina Mollica
        • Dr. Dennis Kim
        • Dr. Pierre Laneuville
        • Dr. Pierre Laneuville (v. fr.)
        • Dr. Conrad Vincent Fernandez
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Mark Hnatiuk
      • CML experts in US >
        • How to get the CMLer's password?
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • Rey Garcia, RN, BSN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Dr. Charles Schiffer
        • Dr. B. Douglas Smith
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Javier Pinilla-Ibarz
        • Dr. Catriona Jamieson
        • Dr. Arul Chinnaiyan
        • Dr. Ami Patel
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Franziska Michor
        • Dr. Frank Giles
        • Dr. Gabriella Hobbs
        • Dr. Ehab Atallah
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Matt Kalaycio
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Ellen K. Ritchie
        • Dr. Karen Seiter
        • Dr. Kendra Sweet
        • Dr. Michael Savona
        • Dr. Neil Shah
        • Dr. Richard T Silver
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Ronald L. Paquette
        • Dr. Sangmin Lee
        • Dr. Srinivas K. Tantravahi
        • Dr. Bin Zhang
      • CML experts in South America >
        • Dr. Michele Bianchini
        • Dra Beatriz Moiraghi
        • Dra. Carla Boquimpani
        • Dr Carolina Pavlovsky
    • CML Experts in Europe >
      • CML Expert in Belgium >
        • Pr Gregor Verhoef
      • CML expert in France >
        • Comment obtenir le mot de passe?
        • Dr. François-Xavier Mahon
        • Dr Aude Charbonnier
        • Dr. Agnès Guerci Bresler
        • Dr Pascale Cony-Makhoul
        • Dr. Delphine Rea
        • Dr. Gabriel Etienne
        • Dr. Lawrence Legros
        • Dr. Marie-Joëlle Mozziconacci
        • Dre Célia SALANOUBAT
        • Pr. Mauricette Michallet
        • Dr. François Guilhot
        • Dr. ​Emilie Cayssial
        • Dr Françoise Huguet
        • Dr. Stéphane Prost
        • Dr. Philippe Rousselot
        • Dr. Eliane Gluckman
        • Dr. Franck-Emmanuel Nicolini
      • CML expert in Italy >
        • Dr. Carlo Gambacorti-Passerini
        • Dr. Chiara Elena
        • Dr. Gianantonio Rosti
        • Dr. Massimo Breccia
        • Dr. Michele Baccarani
        • Dr. Giuseppe Saglio
      • CML expert in UK >
        • Dr. Jane Apperley
        • Dr. Richard Clark
        • Dr. Stephen O'Brien
        • Dr. Georgios Nteliopoulos
        • Dr. Adam Mead
        • Dr. Tessa L Holyoake
      • CML expert in Germany >
        • Dr. Andreas Hochhaus
        • Professor Jörg Hasford
        • Professor Oliver Hantschel​
        • Dr Susanne Saussele
        • Dr. Martin Müller
      • CML expert in Portugal >
        • Dr. Antônio Medina de Almeida
      • CML expert in Spain >
        • Dr. Juan Luis Steegmann
      • CML expert in Netherlands >
        • Dr. Jeroen J.W.M. Janssen
      • CML expert in Sweden >
        • Dr. Johan Richter
      • CML expert in Czech Republic >
        • Dr. Hana Klamova
    • CML experts in Asia >
      • Dr. Annuar Rapaee
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Uday Yanamandra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • CML experts in Africa >
      • Dr. Asmaa Quessar
      • Dr. Anthony Oyekunle
    • CML experts in Australia >
      • Dr. Ilaria Pagani
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. David T. Yeung
      • Dr. Liu Lu
      • Dr. Naranie Shanmuganathan
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • How to get the CMLer's password?
    • Introduction to CML >
      • Precision medicine in chronic myeloid leukemia
      • Philadelphia chromosome
      • BCR-ABL Transcripts
      • Sokal, Hasford, and EUTOS scores
    • General concepts >
      • Blood
      • Bone Marrow
      • DNA
      • Electrolytes
      • Stem Cells
      • Immune System >
        • Natural killer cell - NK
        • T Cells
      • Blood-Brain Barrier
    • Clinical Trials
    • Treatment response in CML
    • Resistance to treatment in CML >
      • Molecular monitoring in CML >
        • Polymerase Chain Reaction (PCR)
        • Dr. Kary Bank Mullis
      • Non-adherence of CML patients
      • Sensitive detection of BCR-ABL1 mutations
      • JAK2 Gene
    • Donor lymphocyte infusion (DLI)
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • How to get the CMLer's password?
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Imatinib
    • Tasigna (Nilotinib) >
      • Generic nilotinib
    • Sprycel (Dasatinib) >
      • Generic Dasatinib
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • Scemblix (Asciminib)
    • Tern-701
    • KF1601
    • Synribo (Omacetaxine )
    • HQP1351 (Olverembatinib)
    • Jakafi (Ruxolitinib)
    • K0706 (Vodobatinib)
    • Flumatinib
    • (Bafetinib)
    • Danusertib
    • DCC-2036 (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • ELVN-001
    • BP1001
    • S116836
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • How to get the CMLer's password?
      • Acid Uric - Gout
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Night Sweats
      • Peripheral Neuropathy in CML
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Food and Drug Interactions
    • CML and comorbidities >
      • Living with CML and diabetes
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Hypnotherapy
      • Music therapy >
        • YouTube creation by CMLer's family
        • Relaxing Music for Stress Relief. Calm Music for Meditation, Sleep, Healing Therapy, Spa
        • Debussy – Relaxing music - Clair de lune et autres...
        • Delicate music for the soul and LIFE, and birdsong soothes the nervous system.
        • Adagio for Strings (Samuel Barber)
        • Amélie Soundtrack ♥ Comptine d'Un Autre Été
        • The song "Disenchanted'
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • How to get the CMLer's password?
    • 30 years and plus survivors >
      • How to get the CMLer's password?
      • Mark Popadick
      • Mary Sullivan
      • Dr. Robert Patenaude -E
      • Skip Duffe
      • Sister Shirley Vaughn
      • Tamera Simonson
    • 20 years and plus survivors >
      • How to get the CMLer's password?
      • Doug Jenson
      • Giora Sharf
      • Joannie Clements
      • Mel Mann
      • Kevin Williams
      • Rich Jones
      • Tanja Fajon
      • Virginia Garner
    • 10 years and plus survivors >
      • How to get the CMLer's password?
      • Dan Sloan
      • Drew Johnston
      • Erin Zammett Ruddy
      • Erin Havel (Author)
      • Gary Gonzales
      • Jan Geissler
      • Jean McGlynn
      • Jo'story
      • ELLE Halliwell (Pregnancy)
      • Kayla Naton (Pregnancy)
      • Leanne
      • Mary Jane Bertram
      • Pat Elliott
      • Rob Shick
      • Tegan Kubler
      • Tom Cleaver
      • Sohag
    • New CMLers >
      • How to get the CMLer's password?
      • Skye Davidson
      • Amanda Steffy
      • Abbi Evans
      • Alyssa
      • Austin Granatowicz
      • Brown Dudley
      • Nigel
      • Katie
      • Kris
      • Ron Robbecke
    • Celebrities with CML >
      • How to get the CMLer's password?
      • Alexa Score
      • Brian Boyle
      • Carlos Carrasco
      • Charlie Schlatter
      • Doris Muramatsu
      • Dr. Richard Rockefeller
      • Greg Lemond
      • Kareem Abdul-Jabar
      • Kelvin Alston
      • Jason Blake
      • Laura Boyd
      • Lee Zeldin
      • Rick Upchurch
      • Roman Reigns
      • Ryan O'Neal
      • Tim Holcomb
    • Suzan Mc Namara and the petition
    • Bud Romine - the first patient
    • Other testimonials
    • Blogs >
      • How to get the CMLer's password?
      • Living with CML
      • Michelle D's Blog
      • Jon's Blog
      • Blogs not recently updated >
        • Access CML Drugs
        • CMKID's blog – Dislodging the bullet - 2012
        • CML Recovery - Stopping KTI -2011
        • Hans's Blog -2012
        • Elizabeth's Blog - my leukemia - 2013journey
        • Elizabeth's Blog - Heart of the rose -2011
        • Joe's Blog - 2012
        • Josh's Blog - 2014
        • Mannan's Blog -2014
        • Ian's Blog -2014
        • Matt's Blog - 2012
        • Matthew's Blog - 2014
        • Michelle's Blog -2012
        • Nayree's Blog -2011
        • Rob's Blog - 2011
  • Global News on CML
    • English - Latest CML News >
      • News -Archives 2023-2022
      • News -Archives 2021-2020
      • News -Archives 2019-2018
      • News - Archives 2017-2016
      • News Archives - 2015-2014
      • News-Archives -2013-2012
      • News - Archives 2011-2001
    • French (Français) - Dernières nouvelles
    • Spanish (Español)-Ultimas noticias
  • Links to other sites, forums and Facebook
    • Sites (English and other languages)
    • Forums (English and other languages)
    • CML on Facebook
    • CML on Twitter
    • Audio Podcast
  • Various topics
    • How to get the CMLer's password?
    • CML patients and the coronavirus
    • You’ve just been diagnosed
    • History of CML
    • CML causes
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • Increased Risk of Secondary Cancers with CML
    • Vaccination of CMLers
    • CML Blast Crisis treatment
    • Bone marrow transplant
    • Stem cells from umbilical cord blood
    • ThINKK (Therapeutic inducers of Natural Killer cell killing)
    • Children with CML
    • CML and pregnancy
    • Mutation T315I
    • Elderly patients with CML
    • Sports with CML
    • CML Awareness Day >
      • Journée mondiale de sensibilisation à la leucémie myéloïde chronique
    • The movie "Dying to Survive"
    • The movie 'The Blue Butterfly"
  • Cure possible for CML?
    • How to get the CMLer's password?
    • Hematopoietic stem cell transplantation using single UM171-expanded cord blood >
      • Greffe de cellules souches de cordon ombilical amplifiées par la molécule UM171
    • Combination of tyrosine kinase inhibitor with other medication >
      • Combinaison of hydroxychloroquine with tyrosine kinase inhibitor
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of insulin sensitizer MSDC-0600K with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
    • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
    • Inhibition of the protein Ezh2 can cure CML?
    • Inhibition of STAT5 in conjunction with standard TKI therapy
    • PROTAC-mediated Targeted Protein Degradation
    • CML vaccine
    • Can immunotherapy cure leukemia?
    • Could fasting cure chronic myeloid leukemia
    • Chimeric Antigen Receptor T-Cell Therapy
    • Can genetic sequencing help to cure leukemia?
    • Can the new drug CX-5461 cure leukemia?
    • CRISPR-Cas9 gene-editing technique
    • Presence of bcr abl fusion transcripts in healthy individua
    • Math could help cure leukemia
    • Natural Medicine >
      • Possible cure for CML in Fish Oil
      • Betel leaf may help fight CML
      • Feverfew extract (parthenolide)
      • Can dandelions kill cancer?
      • Can curcumin cure leukemia?
  • Treatment-Free remission(TFR)
    • The French trial called STIM (Stop Imatinib)
    • De-escalation of treatment
    • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
  • Educational videos (all languages)
    • Educational videos in English
    • Vidéos pédagogiques en français sur la LMC
    • Videos instructivos en español
  • Educational events
  • CML Tool Box (all languages)
    • English tool box >
      • Survey for CMLer who take asciminib
      • Survey for patients who passed TFR (Treatment-Free Remission)
    • French tool box >
      • Sondage pour les patients qui prennent l'asciminib
      • Sondage uniquement auprès des patients ayant réussi le RST( Rémission sans traitement)
    • Spanish tool box >
      • Encuesta_de_medicación_ LMC.html
    • Know your CML
    • My CML
  • CML Glossaries
  • Moral Support
    • Where to get help and support
    • Family support
    • Dances at the Cancer Research Centre
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • Stronger
    • The march toward healing
    • Be happy
  • Professionnel help and literature
    • Dr. Siddhartha Mukherjee
  • Patient Rights
  • New technological advances
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Survey
  • Awards & Recognition
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • DONATE
    • Faire un don
    • DONAR
  • About us
    • Our mission
    • Contact us >
      • Nous contacter >
        • Contácte nos.
Chronic Myeloid Leukemia

Iclusig® (Ponatinib) - Chronic Myeloid Leukemia - CML

 
"Ponatinib (trade name Iclusig /aɪˈkluːsɪɡ/ eye-KLOO-sig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor.[2] Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.[3]
The United States Food and Drug Administration approved the drug as a candidate in December 2012, but temporarily suspended sales on 31 October 2013 because of "the risk of life-threatening blood clots and severe narrowing of blood vessels".[4][5] This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug."
Extract of wikipedia

​See also the List of side effects 
​
SITES
​

Iclusig®(Ponatinib) - Takeda
FORUMS
Ponatinib on Facebook


BLOGS
Hans’s Blog
CLINICAL TRIALS

Ponatinib for CML Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE)

Expanded Access Program of Ponatinib

A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia (OPTIC-2L)

​Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

                           All clinical trials with ponatinib
VIDEOS

Chronic Myeloid Leukemia: Arterial Occlusive Events in the PACE Trial
October 28, 2022, Cancer Network

Efficacy and Toxicity Considerations for Use of Ponatinib
February 24, 2022, CancerNetwork

Optimal Ponatinib Dose Selection for a Given Patient Population
February 24, 2022, CancerNetwork

Clinical Implications of a Dose Ranging Study of Ponatinib for CML
February 17, 2022, CancerNetwork
 
Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia
February 17, 2022, CancerNetwork


VIDEO: Ponatinib dose-optimization beneficial for CML despite cardiac toxicity
July 7, 2021, Healio


VIDEO: High dose ponatinib benefits patients with chronic myeloid leukemia
June 22, 2021, Healio


Ponatinib in chronic-phase CML patients with prior second generation TKI exposure
December 7, 2020, VJHemOnc – Video Journal of Hematological Oncology
 

OPTIC: ponatinib in resistant chronic-phase CML
​
June 30, 2020, VJHemOnc – Video Journal of Hematological Oncology

Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
June 11-21, 2020, The ASCO Post
​
FLAG-IDA and ponatinib in blast phase CML: MATCHPOINT trial
January 24, 2020, VJHemOnc – Video Journal of Hematological Oncology

Dose-Related Adverse Events With Ponatinib When Treating CML
July 29, 2019, Targeted Oncology

Bosutinib Versus Ponatinib in R/R CML
July 22, 2019, Targeted Oncology

Early Intervention With Ponatinib in Treatment of CML
July 17, 2019, Targeted Oncology

Case 2: Ponatinib for T315I-Mutated CML
June 4, 2019, Targeted Oncology

Rationale for TKI Therapy in Relapsed CML
January 22, 2018, Targeted Oncology

Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trial
January 10, 2017,   VJHemOnc 
​
Modelling ponatinib resistance in BCR-ABL1 cell lines
August 3, 2016, ecancer

What are the efficacy and safety considerations in using ponatinib?
April 29, 2016, MediCom Oncology

Management of Thrombosis Risk with Ponatinib and other TKIs for CML?
May 15, 2015, ImedexCME

Epic:Phase 3 Trial of Ponatinib Compared with Imatinib in Newly Diagnosed Chronic Myeloid Leukemia
February 16, 2015, Oncology.TV

Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
February 24, 2014, OncLiveTV

More on Ponatinib and Next Steps - Harry  Erba, MD      
November 7, 2013, NationalCMLSociety

Considerations for Patients Taking Ponatinib - Michael Mauro, MD           
November  5, 2013, NationalCMLSociety·

Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial             
June 14, 2012, OncLive

ARIAD: Xiaotian Zhu on Ponatinib                                                                  
April 3, 2012, Executive video  
   

ARTICLES

Lower-Dose Ponatinib Appears Effective as Induction in Chronic Phase CML
December 11, 2023, Cancer Therapy Advisor


Ponatinib Dose-Ranging Data in Chronic-Phase CML
October 13, 2023, Cancer Network


Olverembatinib in Ponatinib-Resistant CML: Considerations for Later-Line Therapy
October 3, 2023, Cancer Therapy Advisor


Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML
July 28, 2023, Cancer Network


Ponatinib after TKI Failure in Chronic Myeloid Leukemia
November 4, 2022, Cancer Network

Optimal Biologic Dose of Ponatinib Reduces Adverse Events in CP-CML
October 12, 2022, Targeted Oncology

Real-Life Management of Chronic Myeloid Leukemia Patients Treated with Ponatinib
October 10, 2022, Physician Weekly

Ponatinib Yields Benefits Across 3 Dosage Regimens in Chronic-Phase Chronic Myeloid Leukemia
January 12, 2022, Hematology Advisor

Ponatinib, High-Dose Chemo Combo Likely to Benefit High-risk BP-CML
January 1, 2022, AJMC

STAT5 inhibitor Pimozide as a probable therapeutic option in overcoming Ponatinib resistance in K562 leukemic cells
November 28, 2021, PubMed

Dose-Optimization of Ponatinib in Patients With Resistant/Intolerant Chronic-Phase Chronic Myeloid Leukemia
September 10, 2021, Hematology Advisor
​
Registry Data Support Use of Ponatinib in CML, Ph+ ALL Resistant or Intolerant to Tyrosine Kinase Inhibitors
July 5, 2021, Oncology Nurse Advisor

Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
June 5, 2021, Cancer Therapy Advisor
 
Dr Christopher Arendt on OPTIC Findings for Dose Optimization of Ponatinib in Patients With CP-CML
June 5, 2021, AJMC

Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
May 19, 2021, Takeda


Dr. Cortes Discusses Approval of Ponatinib for Adults with Chronic-phase CML
February 5, 2021, docwirenews

FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant Chronic-Phase CML
December 18, 2020, Cancer Network

U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
2020-12-18, Takeda


Ponatinib Demonstrates Efficacy Over Time for Patients With CP-CML After Prior TKI Failure
December 7, 2020,  Targeted Oncology

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
December 7, 2020, ASH 2020

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML
December 7, 2020, ASH 2020

Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance
September 28, 2020, PubMed

Ponatinib starting dose may be linked to efficacy, safety in chronic-phase CML
September 15, 2020, Healio

Ponatinib and Other CML Tyrosine Kinase Inhibitors in Thrombosis
September 8, 2020, International Journal of  Molecular Sciences


Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML
May 29, 2020, Takeda


Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
February 11, 2020, Blood Advance 
​
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management
October 7, 2019, PubMed

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
September 4, 2019, PubMed

Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity
April 2019,  Hong Kong Medical Journal

Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation
March 16, 2019, PubMed

Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors
November 29, 2018, Blood

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
October 15, 2018, Cancer Therapy Advisor

Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study
May 7, 2018, PubMed

Analyst 'would not be surprised' to see Takeda retry Iclusig in first-line CML
March 25, 2018,   The Pharma Letter  

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood
March 22, 2018,  Boston Business Journal

Publication of Final Data from ICLUSIG (ponatinib) Pivotal Phase 2 PACE Trial
March 22, 2018, Drug Discovery & Development

Ponatinib Maintains Benefit in Chronic-Phase CML at 5 Years
March 22, 2018, OncLive

Ponatinib Shows Promise for Rare Ovarian Cancer Type that Affects Young Women
March 8, 2018,  Oncology Nursing News

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
December 2017,  ASH 2017
 
A Conservative Tailoring of Ponatinib Dose in Chronic Myeloid Leukemia Patients Can Diminish Adverse Events While Maintaining Efficacy
December 2017, ASH 2017

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
December 2017, ASH 2017


A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy  in CML Patients
​
​​December 2017, ASH 2017

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting
October 2017, PublMed

Ponatinib: Black Box Warning and Drug Interactions
January 17, 2017,  Cancer Therapy Advisor

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
April 14, 2016, NCBI

Ponatinib and Cardiovascular Complications
December 4, 2016, ASH 2016

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial
December 4, 2016, ASH 2016

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation
December 4, 2016, ASH 2016

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients
December 3, 2016, ASH 2016

Ponatinib Approved for CP-CML Not Indicated for Prior TKI
December 1, 2016,  Cancer Therapy Advisor

Response Rate Similar Between Low- and Standard-dose Ponatinib
September 23, 2016, Cancer Therapy Advisor

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase
June 2016, Haematologica

ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
June 13, 2016, Business Wire

Vascular Events Remain Problem for Ponatinib in CML
Apr 22, 2016‎, Cancer Network

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
April 14, 2016, NCBI

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
April 12, 2016, NCBI

Ponatinib vs Allogeneic SCT Promising for T315I Mutation-positive CP-CML
January 11, 2016, Cancertherapyadvisor

Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON)
June 2015,  2015 ASCO Annual Meeting 

Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.
June 2015,  2015 ASCO Annual Meeting 

Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.
June 2015,  2015 ASCO Annual Meeting     

Long-term Bosutinib in patients with chronic phase  CML after prior  imatinib failure
June 2015,  EHA 2015  

Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the Pace trial 
June 2015,  EHA 2015   

Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the Pace trial 
June 2015,  EHA 2015  

Long-term follow-up of ponatinib effivacy and safety in patients (PTS) with the T315I mutation in the phase 1 and phase 2(pace) trials.
June 2015,  EHA 2015

Elavated  Blood Pressure  ans adverse events of hypertension  in phase 1,2 and 3 trials of ponationib in leukemia
June 2015,  EHA 2015  

T315I clone selectioin in a PH+ All patient under maintenance Ponatinib
June 2015,  EHA 2015

Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph+) CML/ALL patients
June 2, 2014, 2014 ASCO Annual Meeting

Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias
June 2, 2014, 2014 ASCO Annual Meeting

EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML
May 31, 2014, 2014 ASCO Annual Meeting

ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Australia
January 28, 2014, Business Wire

Patients'  advocates press FDA to retain lifesaving drugs  (Iclusig)
November 24, 2013, Boston  Globe

Ariad jumps on  European drug action 
November 23, 2013,
Boston  Globe

European Medicines Agency recommends  changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise
risk of blood clots

November 22, 2013,  European Medicine  Agency

Ponatinib demonstrated activity in  patients with CML, Ph+ALL
November 21, 2013, HemOnctoday

PRAC updates on the risks of serious  vascular occlusive events associated with cancer medicine Iclusig
November 8, 2013, European Medicines  Agency

Doctors Fear  Losing Leukemia Drug Deemed Risky
November 1, 2013, New York Times

The Leukemia  & Lymphoma Society  Issues Statement  Regarding the Status of Iclusig
November 1, 2013, DigitalJournal.com

Serious Danger  of Blood Clots  Halts Sale of Leukemia Drug
October 31, 2013,  New York  Times

Genetic details  of leukemia resistance
October 31, 2013, Oncology Nurse  Advisor

Ariad announces  discontinuation of a trial for its leukemia  drug
October 18, 2013, boston.com

Ariad crushed  (again) after PhIII Iclusig trial is shuttered on blood clot  fears
October 18, 2013, FierceBiotech
 
Ariad Stops  Phase 3 Epic Trial Of Iclusig In Patients With Newly Diagnosed  CML
October 18, 2013, RTT  News

Safety Concerns Halt Ponatinib  Development
October 9, 2013, Onc  LIve

Ponatinib—A Step Forward in Overcoming  Resistance in Chronic Myeloid Leukemia
August 5, 2013, Clinical cancer  Research

Effects of food on the pharmacokinetics  of ponatinib in healthy subjects.
July 25, 2013,  PublMed

New TKI Ponatinib Effective in Resistant  CML
February  2013, Clinical Oncology  News

Ponatinib Could Herald “Revolution”in CML  Treatment
December 20, 2012, OncLive

Ponatinib in Refractory Philadelphia  Chromosome–Positive  Leukemias
November 29, 2012, The  New England  Journal of Medicine

F.D.A. Gives Early Approval to Drug for Rare Leukemia
December 14, 2012,  The New York  Times

OHSU-developed ponatinib wins FDA  approval
December 14, 2012, Portland Business  Journal

FDA grants approval for potential  ‘blockbuster’ leukemia drug made by Cambridge-based Ariad
December 14, 2012, Boston.com

ARIAD Announces Accelerated Approval by FDA of Iclusig (Ponatinib) for Patients with CML and Ph+ ALL Resistant or Intolerant to Prior Tyrosine Kinase Inhibitor Therapy
December 14, 2012, Fierce Biotech
 
FDA Approves Ariad Pharma Leukemia  Drug
December 14, 2012, The Street

Ponatinib  offers new hope in drug-resistant leukemia
December 5, 2012 , News-Medical.net
 
Chronic Myeloid Leukemia Mutation Thwarted By Ponatinib
December 2, 2012,  Science  2.0

Data Published on ARIAD Candidate - Analyst  Blog
November 30, 2012, Nasdaq

In CML, Next-Generation TKIs Aim to Boost  Outcomes
November 30, 2012, Onc  LIve

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia
November 29, 2012, News Medical

Ponatinib for Chronic Myeloid Leukemia
November 29, 2012, The New England  Journal of Medicine

Ponatinib acts against the most resistant types of chronic myeloid leukemia
November 28, 2012, Science Codex

Ponatinib Acts Against the Most Resistant Types of Chronic Myeloid Leukemia
November 28, 2012, Science Daily

FDA Agrees to Speed Review of Ariad Drug
October 25, 2012, DailyFinance

Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
October 1, 2012, Seeking Alpha

ARIAD Announces Submission of Marketing Authorization Application for Ponatinib to the European Medicines Agency
August. 30, 2012, Fierce Pharma.

Ariad Pharmaceuticals Gearing Up For Ponatinib's Approval
August 29, 2012, Seeking  Alpha

ARIAD Pharma initiates phase I/II trial of ponatinib in Japan
August 22, 2012, Pharmabiz.com

Accelerated FDA Approval for CML Drug Ponatinib Sought
August 9, 2012, Cancer Network

Ponatinib Achieves Primary Endpoints in CML Subtypes
August 8, 2012, OncLive

Ariad Prepares for Early Launch of CML Drug Ponatinib
August 6, 2012, Oncology Stat

Ariad speeds targeted leukemia drug to FDA in race for key approval
July 31, 2012, FierceBiotech

Ariad Pharma ANNOUNCES Phase 3 Trial and 4 Stocks Hitting 52-Week Highs
July 28, 2012, Wall St . Cheqt  Sheet

Platelet dysfunction associated with ponatinib, a new  pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to  multiple tyrosine kinase inhibitor therapy
April 24, 2012, Haematologica
Ponatinib Continues to Impress in Patients with Leukemia
February 15, 2012, The ASCO Post ​


Ariad Pharmaceuticals Still Might Have Upside
December 21, 2011, Investor Place

Ariad's ponatinib takes center stage with promising pivotal leukemia data
December 12, 2011, Fierce Biotech

Drug For Chronic Myeloid Leukemia To Be Out Soon
December 12, 2011, TopNews

Initial Findings from the PACE trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+All
Resistant or Intolerant or Dasatinib or Nilotinib, or with the T315I  Mutation

December 2, 2011, ASH Publications

Ariad Pharma: Early Efficacy, Safety of Leukemia Drug 'Striking'
November  7, 2011, The Street

ARIAD Presents New Preclinical Data On Ponatinib In Solid Tumors, Demonstrating Inhibition Of All FGF Receptor Kinases
April 6, 2011,  Business Wire

Phase I Trial Shows Ponatinib May Thwart Most Resistant CML
December 16, 2010,  MD Anderson Cancer Center -  Department of Leukemia

Updated Phase 1 study data of ponatinib in  patients with refractory CML, Ph+ ALL presented at ASH
December 6, 2010 , News medical

Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
December 6, 2010, Oncology Stat
 
ARIAD Announces Initiation Of Ponatinib (AP24534) Pivotal Trial In Drug-Resistant Or Intolerant Chronic Myeloid Leukemia
September 2010, Fierce Biotech

Phase 2 trial of ponatinib for the treatment of chronic myeloid leukemia (CML) and  Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL)
September 2010, MPR


                       See also Mutation T315I
​
   

Our disclaimer       Notre avis de non-responsabilité     Nuestro descargo de responsabilidad
  Privacy Policy              Politique de confidentialité                  Politica de Confidencialidad   
                    
Copyright © 2010-2025 CMLeukemia.com
Protected by Copyscape     DMCA.com Protection Status